Wednesday, September 20, 2017 10:15 PM ET
Incyte (INCY) Insider Makes Significant Share Sale Slowing Buy Trend over Last 90 Days
There was a significant insider sale of Incyte shares today, as revealed in a filing with the SEC as — Herve Hoppenot, Director and Officer — sold 70,502 shares in the company having a market value of approximately $8,421,464. There have been 3 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the acquisition of 100,000 company shares and the disposition of 7,388 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 22,110 shares and have averaged 44,473 shares per transaction over this time period.
The number of insider buy/sell trades at Incyte is greater than that of the 182 peer company average over the last 90-day period. The Biotechnology & Medical Research peer group saw 213 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares traded per transaction by Incyte insiders is lower than its peers. Within the peer group there were 8,327,676 shares purchased and 36,916,945 shares sold with company insiders disposing of 134,222 shares on average over this time period.
To bring into focus significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated in data sourced to create and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.